SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)
NCT00783393
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Astrocytoma
Interventions
DRUG:
Temozolomide
Sponsor
Merck Sharp & Dohme LLC